High dose radionuclide complexes for bone marrow suppression

Abstract

The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

What is claimed is: 
     
       1. A method for the treatment of osteomyelitis comprising:
 administering a composition comprising a ligand-complexed radionuclide to a subject suffering from osteomyelitis under conditions such that said osteomyelitis is reduced. 
 
     
     
       2. The method of  claim 1  wherein the ligand is a bone-targeting ligand. 
     
     
       3. The method of  claim 2  wherein said ligand is a macrocylic aminophosphonic acid. 
     
     
       4. The method of  claim 3 , wherein said ligand is 1,4,7,10-tetraazacyclododecanetetramethylenephosphonic acid (DOTMP). 
     
     
       5. The method of  claim 2 , wherein said ligand is selected from the group consisting of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, nitrilotrimethylenephosphonic acid, tris(2-aminoethyl)aminehexamethylenephosphonic acid, methylene diphosphonate, hydroxymethylenediphosphonate, hydroxyethylidene diphosphonate, and ethane-1-hydroxy-1,1-diphosphonic acid. 
     
     
       6. The method of  claim 5 , wherein said ligand is ethylenediaminetetramethylenephosphonic acid. 
     
     
       7. The method of  claim 1 , wherein said radionuclide is selected from the group consisting of Arsenic-77, Molybdenum-99, Rhodium-105, Lutetium-177, Cadmium-115, Antimony-122, Promethium-149, Osmium-193, Gold-198, Thorium-200, Samarium-153, Yttrium-90, Gadolinium-159, Rhenium-186, Rhenium-188, and Holmium-166. 
     
     
       8. The method of  claim 4  wherein the ligand-complexed radionuclide is  166 Ho-DOTMP. 
     
     
       9. The method of  claim 1  wherein the ligand-complexed radionuclide is administered by injection. 
     
     
       10. The method of  claim 1  wherein the ligand is administered by infusion.